Stored platelet hemostatic phenotype and function is not altered when donors are on testosterone replacement therapy.

TRT donor platelets did not differ significantly from control donor platelets in platelet count.

• Study compared platelets from TRT donors (N=10) and age- and sex-matched control donors (N=10).
• Platelet products were stored at room temperature for 7 days and analyzed on Day 1 (D1) and Day 7 (D7).
• No statistically significant differences in platelet count were observed between groups at either time point.

TRT donor platelets showed no significant differences in surface receptor expression (surface phenotype) compared to control donor platelets.

• Surface receptor expression was measured on D1 and D7.
• Both TRT and control groups were analyzed using flow cytometry or equivalent surface phenotyping methods.
• No significant between-group differences were found in surface phenotype at either storage time point.

Metabolic function of TRT donor platelets was not significantly different from control donor platelets.

• Metabolic parameters assessed included glucose, lactate, and mitochondrial function.
• Measurements were taken on storage D1 and D7.
• No statistically significant differences in metabolic parameters were observed between TRT and control groups.

Platelet aggregation capacity was not significantly different between TRT donors and control donors.

• Aggregation was assessed on D1 and D7 of storage.
• Both groups showed similar ability to aggregate with no statistically significant between-group differences.
• N=10 per group.

Thrombin generation was not significantly different between TRT donor platelets and control donor platelets.

• Thrombin generation was measured at D1 and D7.
• No significant differences were detected between the TRT and control groups.
• This parameter reflects the ability of platelets to support coagulation cascade activity.

Thrombus formation under physiological arterial flow conditions was not significantly different between TRT and control donor platelets.

• Thrombus formation was assessed under arterial flow regimes.
• Both groups showed similar ability to form occlusive thrombus.
• No statistically significant between-group differences were observed at D1 or D7.

Both TRT and control platelet groups exhibited significant loss of hemostatic function by Day 7 compared to Day 1, regardless of donor group.

• Both groups were similar to each other by D7 but had significantly lost hemostatic function compared to D1.
• This decline in function over 7 days of storage was observed across multiple measured parameters.
• The storage-related decline was consistent between TRT and control groups, indicating no differential effect of TRT on storage lesion.

The study was designed with age- and sex-matched TRT and control donors to control for confounding variables.

• N=10 per group (TRT donors and control donors).
• Donors were age- and sex-matched between groups.
• Platelets in plasma were collected and stored at room temperature for 7 days, with analysis at D1 and D7.
• The comprehensive assessment included platelet count, metabolic parameters, surface receptor expression, aggregation, thrombin generation, and thrombus formation.

Red blood cells from therapeutic phlebotomy of TRT donors have been conditionally approved for transfusion, but platelets from TRT donors are not currently approved due to limited data.

• Critical shortages in the national blood supply have prompted re-evaluation of previously overlooked donor sources.
• Limited data exist on the effects of supraphysiologic testosterone on recipient safety and platelet function.
• This study was designed to address that data gap by providing a comprehensive profile of TRT donor platelet phenotype and function.